Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis

by Elena Iemma | Nov 15, 2023

Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases

by Elena Iemma | Dec 23, 2021

Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

by Sarah Moniz | Aug 15, 2018

De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy

by Sarah Moniz | Jan 18, 2018

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

by Adam | Oct 22, 2016

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]